2022
SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies
Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. Cellular Signalling 2022, 94: 110331. PMID: 35398488, DOI: 10.1016/j.cellsig.2022.110331.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaB-cell malignanciesT cell receptorB cell receptorB-cell chronic lymphocytic leukemiaPathological B-cellsPoor clinical outcomeAcute lymphoblastic leukemiaExpression of SykT lymphocyte developmentClinical outcomesAggressive diseaseActivation of NFATAutoimmune diseasesLymphoblastic leukemiaT lymphocytesLymphocytic leukemiaCell lymphomaLymphoid malignanciesB cellsPI3K-pathwayOncogenic driversMalignancyNegative selectionPremalignant cells
2015
STAT5 antagonism of B cell superenhancer networks initiates progenitor B cell leukemia and predicts patient survival (HEM1P.222)
Farrar M, Katerndahl C, Heltemes Harris L, Willette M, Henzler C, Yang R, Silverstein K, Frietze S, Schjerven H, Ramsey L, Hubbard G, Muschen M, Kornblau S. STAT5 antagonism of B cell superenhancer networks initiates progenitor B cell leukemia and predicts patient survival (HEM1P.222). The Journal Of Immunology 2015, 194: 50.5-50.5. DOI: 10.4049/jimmunol.194.supp.50.5.Peer-Reviewed Original ResearchB cell developmentPatient outcomesB cellsB-cell acute lymphoblastic leukemiaProgenitor B cellsCell acute lymphoblastic leukemiaAcute lymphoblastic leukemiaCell developmentDirect clinical relevanceB-cell leukemiaShort remissionsAggressive diseasePatient survivalLymphoblastic leukemiaTranscription factor STAT5Cell leukemiaClinical relevanceTranscriptional programsLeukemiaDegree of antagonismPre-BCRSurvivalSTAT5 activationMicroarray analysisSTAT5